The role of interleukin-6 in diabetic retinal disease: pathophysiology and therapeutic targeting

Area of Science:

• Ophthalmology
• Immunology
• Pharmacology

Background:

• Diabetic retinal diseases, particularly diabetic macular edema (DME), are often treated with anti-vascular endothelial growth factor A (anti-VEGF-A) therapies.
• A significant percentage of patients exhibit suboptimal responses to anti-VEGF-A, with persistent retinal edema and poor visual outcomes due to unaddressed VEGF-independent pathways.
• Inflammation, mediated by Interleukin-6 (IL-6), is a key pathogenic factor in diabetic eye conditions.

Purpose of the Study:

• To review the role of inflammation and IL-6 signaling in diabetic retinal diseases.
• To synthesize emerging evidence on therapeutic strategies targeting IL-6 for DME management.
• To discuss novel monoclonal antibodies targeting IL-6 and dual IL-6/VEGF pathways.

Main Methods:

• Review of preclinical studies on IL-6 signaling mechanisms and effects on the blood-retinal barrier.
• Analysis of the IL-6 buffer system and its signaling pathways (cis-, trans-, cluster).
• Examination of emerging clinical data for selective IL-6 and bispecific IL-6/VEGF antibodies.

Main Results:

• IL-6 signaling, independently and synergistically with VEGF, disrupts the blood-retinal barrier.
• Preclinical data support IL-6 as a therapeutic target in diabetic retinopathy.
• Emerging clinical trials show promise for IL-6 targeting agents in DME.

Conclusions:

• IL-6 plays a critical role in the pathogenesis of diabetic retinal diseases.
• Targeting IL-6 offers a promising strategy to overcome limitations of current anti-VEGF-A therapies.
• Novel IL-6-targeted therapies have the potential to improve efficacy in managing DME.